🏷

Classifications

Harrison's Part

👪

Inheritance

1

Autosomal dominant HP:0000006

Caused by heterozygous SETD2 variants; reported probands include de novo cases.

Autosomal dominant inheritance

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"LLS, RAPAS, and MRD70 are caused by heterozygous variants in the set domain-containing protein 2 (SETD2) gene located on chromosome 3p21.31."

Establishes heterozygous (dominant) inheritance and the chromosomal locus for all three SETD2-associated entities including LLS.

?

Discussions and Knowledge Gaps

1

Why do loss-of-function SETD2 variants cause overgrowth with macrocephaly (Luscan-Lumish syndrome) while recurrent missense variants at codon 1740 of the same gene cause microcephaly and growth failure (Rabin-Pappas syndrome) or a milder isolated intellectual disability (MRD70)?

KNOWLEDGE GAP setd2_allelic_series_lls_rapas_mrd70

Attached to

pathophysiology#SETD2 Haploinsufficiency

This is a genuine and unresolved mechanistic problem, not a severity gradient. Three nosologically distinct entities with separate OMIM numbers arise from one gene, and two of them run in opposite growth directions. The p.Arg1740Trp substitution produces RAPAS with microcephaly, hypotonia, feeding difficulty and failure to thrive; a different substitution at the very same residue, p.Arg1740Gln, produces the milder MRD70; and truncating variants across the gene produce the overgrowth phenotype curated in this entry. A simple dosage model cannot accommodate this, and the authors who delineated the series propose gain of function or an altered epigenetic-regulatory effect for the codon-1740 variants without demonstrating either. Until that is resolved, the practical consequence for curation is concrete: a SETD2 variant is not by itself a Luscan-Lumish diagnosis, and the entity must be assigned from the variant class. The GeneReviews chapter (PMID:34978780) independently corroborates the genotype-phenotype split while declining to make it a nosological one: it singles out c.5218C>T (p.Arg1740Trp) as producing a higher frequency of multiple congenital anomalies, including microcephaly, and treats it as a sub-form of one SETD2 spectrum rather than a distinct disease. The open question is therefore narrower than it first appears - the phenotypic difference is not in dispute, only its mechanism and whether it earns separate disease identity. The primary report delineating the codon-1740 group (PMID:32710489) gives the split concrete numbers: 15 individuals with de novo codon-1740 variants, 12 carrying p.Arg1740Trp and 3 carrying p.Arg1740Gln, whose features differ from LLS. That is a genotype-defined cohort rather than a review assertion, which is why this entry treats the phenotypic difference as established and confines the open question to its mechanism.

Proposed experiments

Functional dissection of the codon-1740 substitutions

setd2_r1740_functional_dissection

Compare H3K36me3 levels, SETD2 chromatin occupancy and transcriptomes in isogenic cells carrying SETD2 p.Arg1740Trp, p.Arg1740Gln, a truncating allele, and a full knockout, to establish whether the codon-1740 variants act as gain-of-function or dominant-negative alleles rather than by dosage loss, and whether the growth-direction reversal tracks a distinct transcriptional signature.

⚙

Pathophysiology

6

SETD2 Haploinsufficiency

Heterozygous loss-of-function variation halves the dosage of SETD2, a SET domain histone methyltransferase. This places Luscan-Lumish syndrome in the writer class of the epigenetic machinery, alongside NSD1 in Sotos syndrome and EZH2 in Weaver syndrome.

histone H3K36 methyltransferase activity (SETD2) GO:0046975 ↓ DECREASED

Downstream

Deficient Histone H3K36 Trimethylation

Deficient Alpha-Tubulin K40 Trimethylation

Show evidence (2 references)

PMID:24852293 SUPPORT Human Clinical

"NSD1 and EZH2 are both histone-modifying enzymes. These two epigenetic writers catalyse two specific post-translational modifications of histones: methylation of histone 3 lysine 36 (H3K36) and lysine 27 (H3K27)."

Context, not direct evidence for this node: the quoted sentence is about NSD1 and EZH2 and does not mention SETD2. It is cited because it establishes the writer-class framing that motivated the search for SETD2 and situates this disorder among the overgrowth chromatinopathies. The SETD2 loss-of-function claim itself rests on the next evidence item.

PMID:37025455 SUPPORT Human Clinical

"Conservative analysis and structural analysis showed that the novel pathogenic variant would loss the conserved domains in the C-terminal region and result in loss of function of SETD2 protein."

Direct evidence that a disease-causing SETD2 variant acts by loss of function, which is the mechanism this trigger node models.

Deficient Histone H3K36 Trimethylation

SETD2 is non-redundantly responsible for H3K36 trimethylation, so reduced SETD2 dosage cannot be compensated by another methyltransferase and H3K36me3 falls. H3K36me3 is a permissive, transcription-coupled mark, so its loss shifts the balance of chromatin states at SETD2 target loci - the same permissive-repressive imbalance the module models, reached here through a histone rather than a DNA mark.

chromatin organization GO:0006325 ⇓ LOSS OF FUNCTION

chromatin GO:0000785

Downstream

Dysregulated Developmental Gene Expression

Show evidence (2 references)

PMID:24852293 SUPPORT Human Clinical

"SETD2 is non-redundantly responsible for H3K36 trimethylation."

Establishes non-redundancy, which is what makes halved SETD2 dosage translate into an uncompensated loss of the H3K36me3 mark.

PMID:28202515 SUPPORT Model Organism

"Setd2 inactivation and subsequent loss of H3K36me3"

Independent in vivo confirmation that inactivating Setd2 causes loss of H3K36me3. Cited only for the enzyme-to-mark link; the tumour-suppressor context of this paper is a somatic-cancer mechanism and is NOT part of the Luscan-Lumish chain.

Deficient Alpha-Tubulin K40 Trimethylation

The second, chromatin-independent arm. SETD2 is a dual-function methyltransferase: besides trimethylating histone H3K36 it methylates alpha-tubulin at lysine 40 (alpha-TubK40me3), a microtubule mark. Reduced SETD2 dosage therefore also depletes alpha-TubK40me3, which promotes tubulin nucleation and microtubule formation. IMPORTANT for conformance: this arm is deliberately NOT wired to the epigenetic machinery module. It is a cytoskeletal, not a chromatin, mechanism, and treating it as a chromatinopathy route would misattribute part of this disorder's neurodevelopmental phenotype.

microtubule cytoskeleton organization GO:0000226 ↓ DECREASED

protein-lysine N-methyltransferase activity (SETD2 acting on alpha-tubulin K40) GO:0016279 ↓ DECREASED

Downstream

Impaired Neuronal Polarization and Migration

Show evidence (2 references)

PMID:32710489 SUPPORT Human Clinical

"The SET domain containing 2, histone lysine methyltransferase encoded by SETD2 is a dual-function methyltransferase for histones and microtubules and plays an important role for transcriptional regulation, genomic stability, and cytoskeletal functions."

Establishes the dual enzymatic identity that makes this a separate arm rather than a downstream consequence of the chromatin defect.

PMID:32710489 SUPPORT Human Clinical

"Specifically, SETD2 is associated with trimethylation of histone H3 at lysine 36 (H3K36me3) and methylation of alpha-tubulin at lysine 40."

Names both marks explicitly, which is the branch point this node models.

Impaired Neuronal Polarization and Migration

The cytoskeletal arm's neurodevelopmental readout. alpha-TubK40me3 is enriched in mouse cerebral cortex during embryonic days 14 to 16, and knocking down SETD2 at E14 causes neuronal migration defects that are rescued by a cytoplasm-localised SETD2 truncation or by an alpha-TubK40me3-mimicking mutant - a rescue that isolates the effect to the tubulin mark rather than to chromatin. This arm therefore reaches the clinical phenotype without passing through transcriptional dysregulation.

neuron CL:0000540

neuron migration GO:0001764 ↓ DECREASED

Downstream

Overgrowth and Neurodevelopmental Phenotype

Show evidence (2 references)

PMID:34226540 SUPPORT Model Organism

"Knockdown of α-tubulin methyltransferase SETD2 at E14 leads to the defects in neuronal migration, which could be restored by overexpressing either a cytoplasm-localized SETD2 truncation or α-TubK40me3-mimicking mutant."

The rescue is what makes this a distinct arm: a cytoplasm-localised SETD2 or a tubulin-mark mimic restores migration, so the defect is attributable to the tubulin methylation rather than to the nuclear chromatin function.

PMID:34226540 SUPPORT Model Organism

"α-TubK40me3 is enriched in mouse cerebral cortex during embryonic day (E)14 to E16."

Establishes the developmental window in which the mark is present, i.e. when this arm is operative.

Dysregulated Developmental Gene Expression

Loss of the permissive H3K36me3 mark dysregulates the developmental transcriptional programs at SETD2 target loci. This is the shared, rate-limiting step across the chromatinopathies and the point at which Luscan-Lumish syndrome converges with Sotos and Weaver syndromes despite acting on different marks.

regulation of DNA-templated transcription GO:0006355 ⇓ LOSS OF FUNCTION nervous system development GO:0007399 ↓ DECREASED

Downstream

Overgrowth and Neurodevelopmental Phenotype

Show evidence (2 references)

PMID:28202515 SUPPORT Other

"H3K36me3 marks nucleosomes positioned along actively transcribed gene bodies, and its loss has been found to disrupt diverse chromatin-related activities such as gene splicing, DNA repair, transcriptional elongation, DNA methylation, and maintenance of genome integrity"

Supplies the missing mechanistic link into this node: H3K36me3 is a mark of actively transcribed gene bodies, and losing it disrupts transcriptional elongation among other chromatin-dependent processes. Evidence source is OTHER because this is a background statement summarising established H3K36me3 biology in the introduction of the cited paper, not that paper's own experimental result; its lung-adenocarcinoma findings are a somatic-cancer mechanism and are not part of this chain.

PMID:29681085 SUPPORT Human Clinical

"The SETD2-related overgrowth syndrome is also called "Luscan-Lumish syndrome" (OMIM 616831) with the clinical characteristics of intellectual disability, speech delay, macrocephaly, facial dysmorphism, and autism spectrum disorders."

Independent report tying the SETD2 lesion to the same composite developmental output, supporting this node as the shared step between the chromatin defect and the clinical phenotype.

Overgrowth and Neurodevelopmental Phenotype

The clinical output: postnatal overgrowth with macrocephaly and tall stature, intellectual disability, speech and motor delay, and autism spectrum disorder. The growth direction is the reverse of most chromatinopathies and the reverse of the RAPAS entity caused by codon-1740 missense variants in the same gene.

learning or memory GO:0007611 ↓ DECREASED

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"an overgrowth disorder with multisystem involvement including intellectual disability, speech delay, autism spectrum disorder (ASD), macrocephaly, tall stature, and motor delay."

States the composite clinical output of the chain in a review of 18 new plus 33 previously reported patients.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

11

Head and Neck 1

Macrocephaly HP:0000256

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"The main clinical features of this condition include macrocephaly, tall stature, intellectual disability, speech delay, autism spectrum disorder (ASD), and motor delay"

Macrocephaly is listed among the main clinical features of LLS.

Musculoskeletal 1

Accelerated skeletal maturation HP:0005616

Show evidence (2 references)

PMID:24852293 SUPPORT Human Clinical

"The two probands shared similar clinical features, including postnatal overgrowth, macrocephaly, obesity, speech delay and advanced carpal ossification."

Advanced carpal ossification in both original probands is accelerated skeletal maturation.

PMID:34978780 SUPPORT Human Clinical

"obesity with generalized overgrowth and advanced bone age"

Independent confirmation from GeneReviews that advanced bone age is part of the SETD2 overgrowth phenotype.

Nervous System 5

Intellectual disability HP:0001249

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"The main clinical features of this condition include macrocephaly, tall stature, intellectual disability, speech delay, autism spectrum disorder (ASD), and motor delay"

Intellectual disability is a core feature of LLS.

Delayed speech and language development HP:0000750

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"The main clinical features of this condition include macrocephaly, tall stature, intellectual disability, speech delay, autism spectrum disorder (ASD), and motor delay"

Speech delay is a core feature of LLS.

Motor delay HP:0001270

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"The main clinical features of this condition include macrocephaly, tall stature, intellectual disability, speech delay, autism spectrum disorder (ASD), and motor delay"

Motor delay is a core feature of LLS.

Autism spectrum disorder Autistic behavior HP:0000729

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"The main clinical features of this condition include macrocephaly, tall stature, intellectual disability, speech delay, autism spectrum disorder (ASD), and motor delay"

ASD is a core feature of LLS.

Ventriculomegaly HP:0002119

Show evidence (1 reference)

PMID:34978780 SUPPORT Human Clinical

"macrocephaly with or without ventriculomegaly"

GeneReviews records ventriculomegaly as a variable accompaniment of the macrocephaly.

Growth 3

Tall stature HP:0000098

Show evidence (1 reference)

PMID:37372360 SUPPORT Human Clinical

"The main clinical features of this condition include macrocephaly, tall stature, intellectual disability, speech delay, autism spectrum disorder (ASD), and motor delay"

Tall stature is listed among the main clinical features of LLS.

Postnatal overgrowth HP:0001548

Show evidence (1 reference)

PMID:24852293 SUPPORT Human Clinical

"The two probands shared similar clinical features, including postnatal overgrowth, macrocephaly, obesity, speech delay and advanced carpal ossification."

Establishes the postnatal timing of the overgrowth in the two original probands.

Obesity HP:0001513

Show evidence (1 reference)

PMID:24852293 SUPPORT Human Clinical

"The two probands shared similar clinical features, including postnatal overgrowth, macrocephaly, obesity, speech delay and advanced carpal ossification."

Obesity was present in both of the original probands reported in the gene-discovery paper.

Other 1

Brain malformation Chiari malformation HP:0002308

Show evidence (1 reference)

PMID:34978780 SUPPORT Human Clinical

"brain malformations (including Chiari I malformation and syringomyelia)"

GeneReviews lists Chiari I malformation among the brain malformations of the SETD2 neurodevelopmental spectrum.

🧬

Genetic Associations

1

SETD2

Gene: SETD2 hgnc:18420 relationship_type: CAUSATIVE

Show evidence (2 references)

PMID:24852293 SUPPORT Human Clinical

"We identified two heterozygous mutations in the SETD2 gene in two patients with 'Sotos-like' syndrome: one missense p.Leu1815Trp de novo mutation in a boy and one nonsense p.Gln274* mutation in an adopted girl."

The original gene-discovery observation establishing SETD2 as causal in this overgrowth phenotype.

PMID:37025455 SUPPORT Human Clinical

"Frameshift mutations and non-sense mutations account for 68.5% of the total 51 SETD2 point mutations, suggesting that Luscan-Lumish syndrome is likely due to loss of function of SETD2."

Quantifies the predominance of truncating variants in the reported SETD2 mutation spectrum, and states the loss-of-function conclusion the authors draw from it - which is the mechanism this entry curates.

💊

Medical Actions

4

Nutritional Management of Obesity

Action: Dietary Intervention NCIT:C15447

Diet and exercise directed at the obesity that accompanies the overgrowth phenotype, with weight monitoring beginning in the second year of life. This is the one disorder-specific management priority in Luscan-Lumish syndrome rather than generic supportive care: obesity is an expected part of the phenotype, and two independent sources single out its prevention.

Show evidence (2 references)

PMID:34978780 SUPPORT Human Clinical

"Nutritional management of obesity to include diet/exercise"

States the recommended management of the obesity component in GeneReviews.

PMID:29681085 SUPPORT Human Clinical

"Additionally, prevention of obesity should be an important point of attention for patients diagnosed with a SETD2-related overgrowth syndrome."

Independent report reaching the same management recommendation, which is why this is curated as a named treatment rather than folded into generic supportive care.

Developmental and Rehabilitative Therapy

Action: Supportive Care NCIT:C15747

Standard treatment for developmental delay and autistic features, alongside management of hypotonia and hypermobility.

Show evidence (1 reference)

PMID:34978780 SUPPORT Human Clinical

"standard treatment for developmental delay / autistic features, seizures, hypothyroidism, precocious puberty, hypotonia/hypermobility, scoliosis, refractive error / strabismus, hearing loss, congenital heart defects, and cryptorchidism"

GeneReviews prescribes standard-of-care management across the neurodevelopmental and systemic manifestations; no SETD2-directed therapy exists.

Surveillance for Treatable Comorbidity

Action: Supportive Care NCIT:C15747

Structured monitoring rather than treatment: annual thyroid function, and clinical evaluation for precocious puberty and scoliosis at each childhood visit. Curated because these are the manifestations that are silent until screened for and are treatable once found.

Show evidence (1 reference)

PMID:34978780 SUPPORT Human Clinical

"annual thyroid-stimulating hormone and free T4; clinical evaluation for precocious puberty and scoliosis at each visit during childhood"

States the specific surveillance schedule recommended for this disorder.

Genetic Counseling

Action: Genetic Counseling NCIT:C15240

Autosomal dominant inheritance with most affected individuals representing simplex cases; 50% transmission risk from an affected parent, and prenatal and preimplantation testing available once the familial variant is known.

Show evidence (1 reference)

PMID:34978780 SUPPORT Human Clinical

"Each child of an individual with a SETD2-NDD has a 50% chance of inheriting the SETD2 pathogenic variant."

Supplies the recurrence figure used in counselling.

🔬

Diagnosis

1

SETD2 molecular genetic testing

Diagnosis rests on identifying a heterozygous SETD2 variant, usually by exome sequencing in a child with overgrowth and developmental delay. Interpretation must place the variant within the SETD2 allelic series, since codon-1740 missense variants indicate RAPAS or MRD70 rather than LLS.

Show evidence (1 reference)

PMID:37025455 SUPPORT Human Clinical

"Peripheral blood samples of the proband and his parents were collected for next-generation sequencing including whole-exome sequencing (WES), copy number variation (CNV) detection and mitochondrial DNA sequencing."

Illustrates the trio exome-sequencing route by which SETD2 variants are identified in practice.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Luscan-Lumish Syndrome:

Sotos syndrome

Overlapping Features The archetypal overgrowth chromatinopathy, caused by NSD1 variants. SETD2 was identified precisely by sequencing H3K36-methylation genes in "Sotos-like" patients who had no NSD1 abnormality.

Show evidence (1 reference)

PMID:24852293 SUPPORT Human Clinical

"We identified two heterozygous mutations in the SETD2 gene in two patients with 'Sotos-like' syndrome"

The original probands were ascertained as Sotos-like, establishing Sotos syndrome as the primary differential.

Weaver syndrome

Overlapping Features Overgrowth condition caused by EZH2, the H3K27 methyltransferase; the other arm of the writer-disorder pair that motivated the search for SETD2.

Show evidence (1 reference)

PMID:24852293 SUPPORT Human Clinical

"Among them, Sotos and Weaver syndromes are clinically well defined and due to heterozygous mutations in NSD1 and EZH2, respectively."

Establishes Weaver syndrome and its gene as the co-differential within the overgrowth chromatinopathies.

{ }

Source YAML

click to show

name: Luscan-Lumish Syndrome
creation_date: "2026-08-22T19:05:00Z"
category: Genetic
synonyms:
- LLS
- SETD2-related overgrowth syndrome
- Sotos-like syndrome due to SETD2 variants
description: >
  Luscan-Lumish syndrome is a Mendelian disorder of the epigenetic machinery
  caused by heterozygous loss-of-function variants in SETD2, the enzyme
  non-redundantly responsible for trimethylation of histone H3 at lysine 36
  (H3K36me3). It sits in the **writer** class, and it was found by looking for
  it: reasoning that Sotos syndrome (NSD1, H3K36) and Weaver syndrome (EZH2,
  H3K27) are both caused by writers of those two chromatin marks, Luscan and
  colleagues sequenced the other H3K36- and H3K27-methylation genes in
  "Sotos-like" patients without NSD1 or EZH2 lesions and recovered SETD2. The
  phenotype is postnatal overgrowth with macrocephaly, tall stature, intellectual
  disability, speech and motor delay, and autism spectrum disorder.

  **SETD2 is one gene with three nosologically distinct disorders, and this entry
  is only one of them.** Luscan-Lumish syndrome follows loss of function.
  A recurrent de novo missense at codon 1740, p.Arg1740Trp, instead causes
  Rabin-Pappas syndrome (RAPAS) - severely impaired development with
  **microcephaly**, hypotonia, feeding difficulty and failure to thrive, i.e.
  growth failure in the *opposite* direction from LLS. A different substitution
  at the same residue, p.Arg1740Gln, causes a third and milder entity,
  intellectual developmental disorder autosomal dominant 70 (MRD70). The
  proposed explanation for the divergence is a gain-of-function or altered
  epigenetic-regulatory effect of the codon-1740 missense variants rather than
  simple dosage loss - which is why this entry is curated at
  loss-of-function LLS and does not absorb the other two. See the discussion
  block: this allelic series is an argument against reading "SETD2 variant" as a
  single diagnosis.

  **The nosology is genuinely unsettled, and this entry follows MONDO rather
  than GeneReviews.** OMIM and MONDO split these as three entities, and this
  entry exists under the MONDO term for one of them. GeneReviews instead
  describes a single spectrum, "SETD2 neurodevelopmental disorders", within
  which the p.Arg1740Trp phenotype is a named sub-form (SETD2-NDD with
  multiple congenital anomalies) rather than a separate disease. Both readings
  agree on the biology - that codon-1740 substitutions behave differently from
  truncating loss of function - and disagree only on whether that difference
  warrants separate disease identity. Curators arriving from the GeneReviews
  framing should expect this entry to be narrower in scope than that chapter.

  **SETD2 has two enzymatic arms, and only one of them is a chromatinopathy
  mechanism.** Besides trimethylating histone H3K36, SETD2 methylates
  alpha-tubulin at lysine 40 - it is a dual-function methyltransferase for
  histones *and* microtubules. The tubulin mark is enriched in mouse cerebral
  cortex at E14-E16 and is required for neuronal polarization and migration;
  knocking SETD2 down at E14 causes migration defects that are rescued by a
  *cytoplasm-localised* SETD2 truncation or by a tubulin-mark mimic, which
  places the defect outside the nucleus. This entry curates both arms, and
  conforms only the chromatin arm to the epigenetic machinery module.
  Attributing the whole neurodevelopmental phenotype to chromatin would
  overstate the module.

  Overgrowth is characteristic but not obligate. Frameshift and nonsense variants
  account for about two thirds of reported SETD2 lesions, and cases with
  loss-of-function variants and developmental delay *without* overgrowth are
  reported, so absence of overgrowth does not exclude the diagnosis.
disease_term:
  preferred_term: Luscan-Lumish syndrome
  term:
    id: MONDO:0014791
    label: Luscan-Lumish syndrome
parents:
- overgrowth syndrome
- syndromic intellectual disability
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
references:
- reference: PMID:24852293
  title: "Mutations in SETD2 cause a novel overgrowth condition."
- reference: PMID:37372360
  title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
- reference: PMID:37025455
  title: "A novel SETD2 variant causing global development delay without overgrowth in a Chinese 3-year-old boy."
- reference: PMID:29681085
  title: "Two novel cases expanding the phenotype of SETD2-related overgrowth syndrome."
- reference: PMID:34978780
  title: "SETD2 Neurodevelopmental Disorders."
  tags:
  - GeneReviews
notes: >-
  Curated as part of a review of Mendelian intellectual disability coverage; the
  disorder was absent from kb/disorders and open in stubs/. Conforms to the
  `epigenetic_machinery_neurodevelopmental_dysregulation` module as a
  **writer-class** conformer, complementing Beck-Fahrner syndrome (eraser class,
  DNA arm) and the histone-acetylation and remodeler conformers already wired.

  Deep-research provenance: `research/Luscan-Lumish_Syndrome-deep-research-openscientist.md`
  (OpenScientist, 2026-08-24). Its own reference validation reports 22/22
  references resolved, 17/17 quoted claims found in source, 0 off topic, and a
  0.0 confabulation rate; `just preflight-dr` against MONDO:0014791 returns
  PASS with SETD2 dominating gene mentions (62) and the report OMIM matching
  the MONDO xref (616831). The report is what surfaced the alpha-tubulin arm,
  which GeneReviews and the clinical literature used here do not cover; every
  claim taken from it was re-verified against the primary papers before
  curation, per the DR discipline in CLAUDE.md.

  Prevalence is not curated as a numeric rate here: the disorder is ultra-rare
  with roughly 50 patients reported in the literature to date, and a firm
  population estimate is not established.

  The SETD2 allelic series (LLS / RAPAS / MRD70) is recorded as a discussion
  rather than as `has_subtypes`, because RAPAS and MRD70 are described in the
  source as nosologically distinct entities with their own OMIM numbers and a
  probably different (gain-of-function) mechanism, not as severity grades of
  this entry. If they are curated later they should be separate entries.
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    Caused by heterozygous SETD2 variants; reported probands include de novo
    cases.
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      LLS, RAPAS, and MRD70 are caused by heterozygous variants in the set
      domain-containing protein 2 (SETD2) gene located on chromosome 3p21.31.
    explanation: >-
      Establishes heterozygous (dominant) inheritance and the chromosomal locus
      for all three SETD2-associated entities including LLS.
genetic:
- name: SETD2
  gene_term:
    preferred_term: SETD2
    term:
      id: hgnc:18420
      label: SETD2
  relationship_type: CAUSATIVE
  notes: >-
    Heterozygous loss-of-function SETD2 variants cause Luscan-Lumish syndrome.
    Frameshift and nonsense variants predominate among reported SETD2 lesions.
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified two heterozygous mutations in the SETD2 gene in two patients
      with 'Sotos-like' syndrome: one missense p.Leu1815Trp de novo mutation in a
      boy and one nonsense p.Gln274* mutation in an adopted girl.
    explanation: >-
      The original gene-discovery observation establishing SETD2 as causal in
      this overgrowth phenotype.
  - reference: PMID:37025455
    reference_title: "A novel SETD2 variant causing global development delay without overgrowth in a Chinese 3-year-old boy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frameshift mutations and non-sense mutations account for 68.5% of the total
      51 SETD2 point mutations, suggesting that Luscan-Lumish syndrome is likely
      due to loss of function of SETD2.
    explanation: >-
      Quantifies the predominance of truncating variants in the reported SETD2
      mutation spectrum, and states the loss-of-function conclusion the authors
      draw from it - which is the mechanism this entry curates.
pathophysiology:
- name: SETD2 Haploinsufficiency
  description: >-
    Heterozygous loss-of-function variation halves the dosage of SETD2, a SET
    domain histone methyltransferase. This places Luscan-Lumish syndrome in the
    writer class of the epigenetic machinery, alongside NSD1 in Sotos syndrome
    and EZH2 in Weaver syndrome.
  role: trigger
  biological_scale: MOLECULAR
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Epigenetic Machinery Component Haploinsufficiency"
  molecular_functions:
  - preferred_term: histone H3K36 methyltransferase activity (SETD2)
    term:
      id: GO:0046975
      label: histone H3K36 methyltransferase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      NSD1 and EZH2 are both histone-modifying enzymes. These two epigenetic
      writers catalyse two specific post-translational modifications of histones:
      methylation of histone 3 lysine 36 (H3K36) and lysine 27 (H3K27).
    explanation: >-
      Context, not direct evidence for this node: the quoted sentence is about
      NSD1 and EZH2 and does not mention SETD2. It is cited because it
      establishes the writer-class framing that motivated the search for SETD2
      and situates this disorder among the overgrowth chromatinopathies. The
      SETD2 loss-of-function claim itself rests on the next evidence item.
  - reference: PMID:37025455
    reference_title: "A novel SETD2 variant causing global development delay without overgrowth in a Chinese 3-year-old boy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Conservative analysis and structural analysis showed that the novel
      pathogenic variant would loss the conserved domains in the C-terminal
      region and result in loss of function of SETD2 protein.
    explanation: >-
      Direct evidence that a disease-causing SETD2 variant acts by loss of
      function, which is the mechanism this trigger node models.
  downstream:
  - target: Deficient Histone H3K36 Trimethylation
    causal_link_type: DIRECT
  - target: Deficient Alpha-Tubulin K40 Trimethylation
    causal_link_type: DIRECT

- name: Deficient Histone H3K36 Trimethylation
  description: >-
    SETD2 is non-redundantly responsible for H3K36 trimethylation, so reduced
    SETD2 dosage cannot be compensated by another methyltransferase and H3K36me3
    falls. H3K36me3 is a permissive, transcription-coupled mark, so its loss
    shifts the balance of chromatin states at SETD2 target loci - the same
    permissive-repressive imbalance the module models, reached here through a
    histone rather than a DNA mark.
  role: amplifier
  biological_scale: MOLECULAR
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Permissive-Repressive Chromatin State Imbalance"
  biological_processes:
  - preferred_term: chromatin organization
    term:
      id: GO:0006325
      label: chromatin organization
    modifier: LOSS_OF_FUNCTION
  cellular_components:
  - preferred_term: chromatin
    term:
      id: GO:0000785
      label: chromatin
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SETD2 is non-redundantly responsible for H3K36 trimethylation.
    explanation: >-
      Establishes non-redundancy, which is what makes halved SETD2 dosage
      translate into an uncompensated loss of the H3K36me3 mark.
  - reference: PMID:28202515
    reference_title: Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Setd2 inactivation and subsequent loss of H3K36me3
    explanation: >-
      Independent in vivo confirmation that inactivating Setd2 causes loss of
      H3K36me3. Cited only for the enzyme-to-mark link; the tumour-suppressor
      context of this paper is a somatic-cancer mechanism and is NOT part of the
      Luscan-Lumish chain.
  downstream:
  - target: Dysregulated Developmental Gene Expression
    causal_link_type: DIRECT

- name: Deficient Alpha-Tubulin K40 Trimethylation
  description: >-
    The second, chromatin-independent arm. SETD2 is a dual-function
    methyltransferase: besides trimethylating histone H3K36 it methylates
    alpha-tubulin at lysine 40 (alpha-TubK40me3), a microtubule mark. Reduced
    SETD2 dosage therefore also depletes alpha-TubK40me3, which promotes tubulin
    nucleation and microtubule formation. IMPORTANT for conformance: this arm is
    deliberately NOT wired to the epigenetic machinery module. It is a
    cytoskeletal, not a chromatin, mechanism, and treating it as a chromatinopathy
    route would misattribute part of this disorder's neurodevelopmental phenotype.
  role: amplifier
  biological_scale: MOLECULAR
  molecular_functions:
  - preferred_term: protein-lysine N-methyltransferase activity (SETD2 acting on alpha-tubulin K40)
    term:
      id: GO:0016279
      label: protein-lysine N-methyltransferase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: microtubule cytoskeleton organization
    term:
      id: GO:0000226
      label: microtubule cytoskeleton organization
    modifier: DECREASED
  evidence:
  - reference: PMID:32710489
    reference_title: Genotype-phenotype correlation at codon 1740 of SETD2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The SET domain containing 2, histone lysine methyltransferase encoded by
      SETD2 is a dual-function methyltransferase for histones and microtubules
      and plays an important role for transcriptional regulation, genomic
      stability, and cytoskeletal functions.
    explanation: >-
      Establishes the dual enzymatic identity that makes this a separate arm
      rather than a downstream consequence of the chromatin defect.
  - reference: PMID:32710489
    reference_title: Genotype-phenotype correlation at codon 1740 of SETD2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Specifically, SETD2 is associated with trimethylation of histone H3 at
      lysine 36 (H3K36me3) and methylation of alpha-tubulin at lysine 40.
    explanation: >-
      Names both marks explicitly, which is the branch point this node models.
  downstream:
  - target: Impaired Neuronal Polarization and Migration
    causal_link_type: DIRECT

- name: Impaired Neuronal Polarization and Migration
  description: >-
    The cytoskeletal arm's neurodevelopmental readout. alpha-TubK40me3 is
    enriched in mouse cerebral cortex during embryonic days 14 to 16, and
    knocking down SETD2 at E14 causes neuronal migration defects that are
    rescued by a cytoplasm-localised SETD2 truncation or by an
    alpha-TubK40me3-mimicking mutant - a rescue that isolates the effect to the
    tubulin mark rather than to chromatin. This arm therefore reaches the
    clinical phenotype without passing through transcriptional dysregulation.
  role: effector
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: neuron migration
    term:
      id: GO:0001764
      label: neuron migration
    modifier: DECREASED
  evidence:
  - reference: PMID:34226540
    reference_title: alpha-TubK40me3 is required for neuronal polarization and migration by promoting microtubule formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Knockdown of α-tubulin methyltransferase SETD2 at E14 leads to the defects
      in neuronal migration, which could be restored by overexpressing either a
      cytoplasm-localized SETD2 truncation or α-TubK40me3-mimicking mutant.
    explanation: >-
      The rescue is what makes this a distinct arm: a cytoplasm-localised SETD2
      or a tubulin-mark mimic restores migration, so the defect is attributable
      to the tubulin methylation rather than to the nuclear chromatin function.
  - reference: PMID:34226540
    reference_title: alpha-TubK40me3 is required for neuronal polarization and migration by promoting microtubule formation.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      α-TubK40me3 is enriched in mouse cerebral cortex during embryonic day
      (E)14 to E16.
    explanation: >-
      Establishes the developmental window in which the mark is present, i.e.
      when this arm is operative.
  downstream:
  - target: Overgrowth and Neurodevelopmental Phenotype
    causal_link_type: DIRECT

- name: Dysregulated Developmental Gene Expression
  description: >-
    Loss of the permissive H3K36me3 mark dysregulates the developmental
    transcriptional programs at SETD2 target loci. This is the shared, rate-limiting
    step across the chromatinopathies and the point at which Luscan-Lumish
    syndrome converges with Sotos and Weaver syndromes despite acting on
    different marks.
  role: central_effector
  biological_scale: MOLECULAR
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Dysregulated Neurodevelopmental Transcriptional Program"
  biological_processes:
  - preferred_term: regulation of DNA-templated transcription
    term:
      id: GO:0006355
      label: regulation of DNA-templated transcription
    modifier: LOSS_OF_FUNCTION
  - preferred_term: nervous system development
    term:
      id: GO:0007399
      label: nervous system development
    modifier: DECREASED
  evidence:
  - reference: PMID:28202515
    reference_title: Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      H3K36me3 marks nucleosomes positioned along actively transcribed gene
      bodies, and its loss has been found to disrupt diverse chromatin-related
      activities such as gene splicing, DNA repair, transcriptional elongation,
      DNA methylation, and maintenance of genome integrity
    explanation: >-
      Supplies the missing mechanistic link into this node: H3K36me3 is a mark of
      actively transcribed gene bodies, and losing it disrupts transcriptional
      elongation among other chromatin-dependent processes. Evidence source is
      OTHER because this is a background statement summarising established
      H3K36me3 biology in the introduction of the cited paper, not that paper's
      own experimental result; its lung-adenocarcinoma findings are a
      somatic-cancer mechanism and are not part of this chain.
  - reference: PMID:29681085
    reference_title: Two novel cases expanding the phenotype of SETD2-related overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The SETD2-related overgrowth syndrome is also called "Luscan-Lumish
      syndrome" (OMIM 616831) with the clinical characteristics of intellectual
      disability, speech delay, macrocephaly, facial dysmorphism, and autism
      spectrum disorders.
    explanation: >-
      Independent report tying the SETD2 lesion to the same composite
      developmental output, supporting this node as the shared step between the
      chromatin defect and the clinical phenotype.
  downstream:
  - target: Overgrowth and Neurodevelopmental Phenotype
    causal_link_type: DIRECT

- name: Overgrowth and Neurodevelopmental Phenotype
  description: >-
    The clinical output: postnatal overgrowth with macrocephaly and tall stature,
    intellectual disability, speech and motor delay, and autism spectrum disorder.
    The growth direction is the reverse of most chromatinopathies and the reverse
    of the RAPAS entity caused by codon-1740 missense variants in the same gene.
  role: consequence
  biological_scale: ORGANISM
  conforms_to: "epigenetic_machinery_neurodevelopmental_dysregulation#Intellectual Disability with Growth and Craniofacial Dysmorphism"
  biological_processes:
  - preferred_term: learning or memory
    term:
      id: GO:0007611
      label: learning or memory
    modifier: DECREASED
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an overgrowth disorder with multisystem involvement including intellectual
      disability, speech delay, autism spectrum disorder (ASD), macrocephaly,
      tall stature, and motor delay.
    explanation: >-
      States the composite clinical output of the chain in a review of 18 new
      plus 33 previously reported patients.
phenotypes:
- category: Growth
  name: Macrocephaly
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main clinical features of this condition include macrocephaly, tall
      stature, intellectual disability, speech delay, autism spectrum disorder
      (ASD), and motor delay
    explanation: Macrocephaly is listed among the main clinical features of LLS.
- category: Growth
  name: Tall stature
  phenotype_term:
    preferred_term: Tall stature
    term:
      id: HP:0000098
      label: Tall stature
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main clinical features of this condition include macrocephaly, tall
      stature, intellectual disability, speech delay, autism spectrum disorder
      (ASD), and motor delay
    explanation: Tall stature is listed among the main clinical features of LLS.
- category: Growth
  name: Postnatal overgrowth
  description: >-
    Overgrowth is postnatal rather than prenatal, and is characteristic but not
    obligate - loss-of-function cases without overgrowth are reported.
  phenotype_term:
    preferred_term: Overgrowth
    term:
      id: HP:0001548
      label: Overgrowth
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The two probands shared similar clinical features, including postnatal
      overgrowth, macrocephaly, obesity, speech delay and advanced carpal
      ossification.
    explanation: >-
      Establishes the postnatal timing of the overgrowth in the two original
      probands.
- category: Neurologic
  name: Intellectual disability
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main clinical features of this condition include macrocephaly, tall
      stature, intellectual disability, speech delay, autism spectrum disorder
      (ASD), and motor delay
    explanation: Intellectual disability is a core feature of LLS.
- category: Neurologic
  name: Delayed speech and language development
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main clinical features of this condition include macrocephaly, tall
      stature, intellectual disability, speech delay, autism spectrum disorder
      (ASD), and motor delay
    explanation: Speech delay is a core feature of LLS.
- category: Neurologic
  name: Motor delay
  phenotype_term:
    preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main clinical features of this condition include macrocephaly, tall
      stature, intellectual disability, speech delay, autism spectrum disorder
      (ASD), and motor delay
    explanation: Motor delay is a core feature of LLS.
- category: Behavioral
  name: Autism spectrum disorder
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:37372360
    reference_title: "Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main clinical features of this condition include macrocephaly, tall
      stature, intellectual disability, speech delay, autism spectrum disorder
      (ASD), and motor delay
    explanation: ASD is a core feature of LLS.
- category: Growth
  name: Obesity
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The two probands shared similar clinical features, including postnatal
      overgrowth, macrocephaly, obesity, speech delay and advanced carpal
      ossification.
    explanation: >-
      Obesity was present in both of the original probands reported in the
      gene-discovery paper.
- category: Skeletal
  name: Accelerated skeletal maturation
  description: >-
    Advanced bone age; reported as advanced carpal ossification in the two
    original probands and as advanced bone age in the GeneReviews description of
    the SETD2 spectrum.
  phenotype_term:
    preferred_term: Accelerated skeletal maturation
    term:
      id: HP:0005616
      label: Accelerated skeletal maturation
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The two probands shared similar clinical features, including postnatal
      overgrowth, macrocephaly, obesity, speech delay and advanced carpal
      ossification.
    explanation: >-
      Advanced carpal ossification in both original probands is accelerated
      skeletal maturation.
  - reference: PMID:34978780
    reference_title: "SETD2 Neurodevelopmental Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      obesity with generalized overgrowth and advanced bone age
    explanation: >-
      Independent confirmation from GeneReviews that advanced bone age is part of
      the SETD2 overgrowth phenotype.
- category: Neurologic
  name: Brain malformation
  description: >-
    Chiari I malformation and syringomyelia are reported in the SETD2 spectrum,
    with ventriculomegaly accompanying macrocephaly in some individuals.
  phenotype_term:
    preferred_term: Chiari malformation
    term:
      id: HP:0002308
      label: Chiari malformation
  evidence:
  - reference: PMID:34978780
    reference_title: "SETD2 Neurodevelopmental Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      brain malformations (including Chiari I malformation and syringomyelia)
    explanation: >-
      GeneReviews lists Chiari I malformation among the brain malformations of
      the SETD2 neurodevelopmental spectrum.
- category: Neurologic
  name: Ventriculomegaly
  phenotype_term:
    preferred_term: Ventriculomegaly
    term:
      id: HP:0002119
      label: Ventriculomegaly
  evidence:
  - reference: PMID:34978780
    reference_title: "SETD2 Neurodevelopmental Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      macrocephaly with or without ventriculomegaly
    explanation: >-
      GeneReviews records ventriculomegaly as a variable accompaniment of the
      macrocephaly.
diagnosis:
- name: SETD2 molecular genetic testing
  description: >-
    Diagnosis rests on identifying a heterozygous SETD2 variant, usually by
    exome sequencing in a child with overgrowth and developmental delay.
    Interpretation must place the variant within the SETD2 allelic series, since
    codon-1740 missense variants indicate RAPAS or MRD70 rather than LLS.
  evidence:
  - reference: PMID:37025455
    reference_title: "A novel SETD2 variant causing global development delay without overgrowth in a Chinese 3-year-old boy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Peripheral blood samples of the proband and his parents were collected for
      next-generation sequencing including whole-exome sequencing (WES), copy
      number variation (CNV) detection and mitochondrial DNA sequencing.
    explanation: >-
      Illustrates the trio exome-sequencing route by which SETD2 variants are
      identified in practice.
treatments:
- name: Nutritional Management of Obesity
  description: >-
    Diet and exercise directed at the obesity that accompanies the overgrowth
    phenotype, with weight monitoring beginning in the second year of life. This
    is the one disorder-specific management priority in Luscan-Lumish syndrome
    rather than generic supportive care: obesity is an expected part of the
    phenotype, and two independent sources single out its prevention.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Dietary Intervention
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:34978780
    reference_title: "SETD2 Neurodevelopmental Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Nutritional management of obesity to include diet/exercise
    explanation: >-
      States the recommended management of the obesity component in GeneReviews.
  - reference: PMID:29681085
    reference_title: Two novel cases expanding the phenotype of SETD2-related overgrowth syndrome.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, prevention of obesity should be an important point of
      attention for patients diagnosed with a SETD2-related overgrowth syndrome.
    explanation: >-
      Independent report reaching the same management recommendation, which is
      why this is curated as a named treatment rather than folded into generic
      supportive care.
- name: Developmental and Rehabilitative Therapy
  description: >-
    Standard treatment for developmental delay and autistic features, alongside
    management of hypotonia and hypermobility.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:34978780
    reference_title: "SETD2 Neurodevelopmental Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      standard treatment for developmental delay / autistic features, seizures,
      hypothyroidism, precocious puberty, hypotonia/hypermobility, scoliosis,
      refractive error / strabismus, hearing loss, congenital heart defects, and
      cryptorchidism
    explanation: >-
      GeneReviews prescribes standard-of-care management across the
      neurodevelopmental and systemic manifestations; no SETD2-directed therapy
      exists.
- name: Surveillance for Treatable Comorbidity
  description: >-
    Structured monitoring rather than treatment: annual thyroid function, and
    clinical evaluation for precocious puberty and scoliosis at each childhood
    visit. Curated because these are the manifestations that are silent until
    screened for and are treatable once found.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:34978780
    reference_title: "SETD2 Neurodevelopmental Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      annual thyroid-stimulating hormone and free T4; clinical evaluation for
      precocious puberty and scoliosis at each visit during childhood
    explanation: >-
      States the specific surveillance schedule recommended for this disorder.
- name: Genetic Counseling
  description: >-
    Autosomal dominant inheritance with most affected individuals representing
    simplex cases; 50% transmission risk from an affected parent, and prenatal
    and preimplantation testing available once the familial variant is known.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:34978780
    reference_title: "SETD2 Neurodevelopmental Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Each child of an individual with a SETD2-NDD has a 50% chance of
      inheriting the SETD2 pathogenic variant.
    explanation: >-
      Supplies the recurrence figure used in counselling.
differential_diagnoses:
- name: Sotos syndrome
  description: >-
    The archetypal overgrowth chromatinopathy, caused by NSD1 variants. SETD2 was
    identified precisely by sequencing H3K36-methylation genes in "Sotos-like"
    patients who had no NSD1 abnormality.
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified two heterozygous mutations in the SETD2 gene in two patients
      with 'Sotos-like' syndrome
    explanation: >-
      The original probands were ascertained as Sotos-like, establishing Sotos
      syndrome as the primary differential.
- name: Weaver syndrome
  description: >-
    Overgrowth condition caused by EZH2, the H3K27 methyltransferase; the other
    arm of the writer-disorder pair that motivated the search for SETD2.
  evidence:
  - reference: PMID:24852293
    reference_title: "Mutations in SETD2 cause a novel overgrowth condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among them, Sotos and Weaver syndromes are clinically well defined and due
      to heterozygous mutations in NSD1 and EZH2, respectively.
    explanation: >-
      Establishes Weaver syndrome and its gene as the co-differential within the
      overgrowth chromatinopathies.
discussions:
- discussion_id: setd2_allelic_series_lls_rapas_mrd70
  kind: KNOWLEDGE_GAP
  prompt: >-
    Why do loss-of-function SETD2 variants cause overgrowth with macrocephaly
    (Luscan-Lumish syndrome) while recurrent missense variants at codon 1740 of
    the same gene cause microcephaly and growth failure (Rabin-Pappas syndrome)
    or a milder isolated intellectual disability (MRD70)?
  attaches_to:
  - "pathophysiology#SETD2 Haploinsufficiency"
  rationale: >-
    This is a genuine and unresolved mechanistic problem, not a severity
    gradient. Three nosologically distinct entities with separate OMIM numbers
    arise from one gene, and two of them run in opposite growth directions. The
    p.Arg1740Trp substitution produces RAPAS with microcephaly, hypotonia,
    feeding difficulty and failure to thrive; a different substitution at the
    very same residue, p.Arg1740Gln, produces the milder MRD70; and truncating
    variants across the gene produce the overgrowth phenotype curated in this
    entry. A simple dosage model cannot accommodate this, and the authors who
    delineated the series propose gain of function or an altered
    epigenetic-regulatory effect for the codon-1740 variants without
    demonstrating either. Until that is resolved, the practical consequence for
    curation is concrete: a SETD2 variant is not by itself a Luscan-Lumish
    diagnosis, and the entity must be assigned from the variant class.

    The GeneReviews chapter (PMID:34978780) independently corroborates the
    genotype-phenotype split while declining to make it a nosological one: it
    singles out c.5218C>T (p.Arg1740Trp) as producing a higher frequency of
    multiple congenital anomalies, including microcephaly, and treats it as a
    sub-form of one SETD2 spectrum rather than a distinct disease. The open
    question is therefore narrower than it first appears - the phenotypic
    difference is not in dispute, only its mechanism and whether it earns
    separate disease identity.

    The primary report delineating the codon-1740 group (PMID:32710489) gives
    the split concrete numbers: 15 individuals with de novo codon-1740
    variants, 12 carrying p.Arg1740Trp and 3 carrying p.Arg1740Gln, whose
    features differ from LLS. That is a genotype-defined cohort rather than a
    review assertion, which is why this entry treats the phenotypic difference
    as established and confines the open question to its mechanism.
  proposed_experiments:
  - experiment_id: setd2_r1740_functional_dissection
    name: Functional dissection of the codon-1740 substitutions
    description: >-
      Compare H3K36me3 levels, SETD2 chromatin occupancy and transcriptomes in
      isogenic cells carrying SETD2 p.Arg1740Trp, p.Arg1740Gln, a truncating
      allele, and a full knockout, to establish whether the codon-1740 variants
      act as gain-of-function or dominant-negative alleles rather than by dosage
      loss, and whether the growth-direction reversal tracks a distinct
      transcriptional signature.

📚

References & Deep Research

References

5

PMID:24852293

Mutations in SETD2 cause a novel overgrowth condition.

No top-level findings curated for this source.

PMID:37372360

Clinical Heterogeneity and Different Phenotypes in Patients with SETD2 Variants: 18 New Patients and Review of the Literature.

No top-level findings curated for this source.

PMID:37025455

A novel SETD2 variant causing global development delay without overgrowth in a Chinese 3-year-old boy.

No top-level findings curated for this source.

PMID:29681085

Two novel cases expanding the phenotype of SETD2-related overgrowth syndrome.

No top-level findings curated for this source.

PMID:34978780

SETD2 Neurodevelopmental Disorders.

No top-level findings curated for this source.

Deep Research

1

OpenScientist ▸

Luscan-Lumish Syndrome: Comprehensive Disease Characteristics Report

openscientist-autonomous 19 citations 2026-08-24T16:12:53.354894

Luscan-Lumish Syndrome: Comprehensive Disease Characteristics Report

Disease Name: Luscan-Lumish Syndrome (LLS) MONDO ID: MONDO:0014916 OMIM (phenotype): #616831 · OMIM (gene): 612778 · Orphanet: ORPHA:457485 Category: Genetic (autosomal dominant overgrowth + neurodevelopmental disorder) Causal Gene: SETD2* (HGNC:18420; NCBI Gene 29072; UniProt Q9BYW2; chromosome 3p21.31)

Summary

Luscan-Lumish syndrome (LLS) is an ultra-rare, autosomal-dominant overgrowth and neurodevelopmental disorder caused by heterozygous, near-universally de novo loss-of-function (LoF) variants in SETD2, the sole somatic histone H3 lysine-36 trimethyltransferase (H3K36me3). First delineated by Lumish and colleagues in 2015 in a girl with autism, intellectual disability, seizures, Chiari I malformation, and macrocephaly carrying a de novo frameshift variant (c.2028delT, p.P677LfsX19), the condition has since been reported in approximately 50 patients worldwide. The core clinical picture combines postnatal overgrowth — macrocephaly (near-universal), tall/advanced stature, and obesity (~50%) — with a highly penetrant neurodevelopmental and behavioral phenotype: intellectual disability (~83%), autism spectrum disorder (~89%), and behavioral difficulties (~100%), often with aggressive outbursts (~83%), speech and motor delay, and advanced carpal (bone) ossification. LLS is classified within the "Sotos-like" family of epigenetic overgrowth syndromes.

The molecular basis is dual. SETD2 is a "chromatocytoskeletal" dual-function methyltransferase: it writes H3K36me3 — essential for transcriptional fidelity (suppression of cryptic transcription), splicing, DNA repair, and genomic stability — and it also methylates α-tubulin at Lys40 (α-TubK40me3) and actin, linking it to microtubule/cytoskeletal function. Haploinsufficiency therefore simultaneously perturbs chromatin regulation and cytoskeletal dynamics. Model-organism work directly ties both arms to the phenotype: the H2A.z–Setd2–H3K36me3 axis drives embryonic cortical neurogenesis (via Nkx2-4), and α-TubK40me3 is required for neuronal polarization and migration in the developing cortex, as well as for mitotic-spindle integrity.

Diagnosis is molecular — trio whole-exome or whole-genome sequencing, or overgrowth/intellectual-disability multigene panels — now reinforced by a distinctive SETD2 DNA-methylation episignature (EpiSign) that supports diagnosis and reclassifies variants of uncertain significance. Importantly, a genotype–phenotype dichotomy exists at the same locus: recurrent de novo missense variants at codon 1740 produce clinically distinct, more severe, growth-restricted disorders — Rabin-Pappas syndrome (RAPAS, p.Arg1740Trp; MIM 620155) and autosomal-dominant intellectual developmental disorder 70 (MRD70, p.Arg1740Gln) — implying a non-LoF (e.g., gain-of-function or altered epigenetic-regulation) mechanism rather than simple haploinsufficiency. No disease-specific or curative therapy exists; management is entirely supportive and multidisciplinary.

1. Disease Information

LLS is a monogenic overgrowth-with-intellectual-disability syndrome in the "Sotos-like" group. It is characterized by "postnatal overgrowth, macrocephaly, obesity, speech delay, and advanced carpal ossification" together with a strongly penetrant neurodevelopmental/behavioral profile (PMID: 31643139).

Key identifiers: - OMIM (phenotype): #616831 (Luscan-Lumish syndrome) - OMIM (gene): 612778 (SETD2) - Orphanet: ORPHA:457485 - MONDO: MONDO:0014916 - MeSH / ICD: No dedicated MeSH heading or specific ICD-10 code; captured under broad codes for congenital malformation syndromes / intellectual disability. ICD-11 would map to a rare-syndrome/developmental-anomaly category. - HGNC: HGNC:18420 (SETD2*)

Synonyms / alternative names: SETD2-related overgrowth syndrome; SETD2-related disorder; intellectual disability, autosomal dominant, with overgrowth (historical descriptions). Note that "SETD2-related disorders" is an umbrella now spanning three nosologically distinct entities: LLS, MRD70, and RAPAS (PMID: 37372360).

Source of information: Aggregated disease-level knowledge from published case reports/series (~50 patients) and mechanistic/model-organism studies — not from a large EHR cohort.

2. Etiology

Primary cause (genetic). LLS is caused by heterozygous, intragenic loss-of-function variants in SETD2. Constitutional SETD2 mutations are "intragenic loss-of-function variants with truncating (69%) and missense (31%) mutations" (PMID: 31643139). The founding case carried a de novo frameshift: "a de novo c.2028delT (P677LfsX19) mutation in the SET domain-containing protein 2 (SETD2) gene, predicted to be gene-damaging" (PMID: 26084711).

Genetic risk factors. The causal event is the SETD2 LoF variant itself, arising de novo; there are no known susceptibility loci or modifier genes established for LLS. Large 3p21.31 deletions encompassing SETD2 can reproduce part of the phenotype (PMID: 27385966).

Environmental risk factors / protective factors / gene–environment interactions. None established. As a de novo dominant Mendelian disorder, LLS has no recognized environmental, lifestyle, or infectious contribution, and no protective alleles or GxE interactions have been reported. Advanced paternal age is a general (non-specific) consideration for de novo single-nucleotide variants but is not documented specifically for LLS.

3. Phenotypes

Per-phenotype frequencies derive chiefly from the Marzin (2019) cohort (n=13): "neurodevelopmental disorders are common such as intellectual disability (83%), autism spectrum disorders (89%), and behavioral difficulties (100%) with aggressive outbursts (83%). A variety of features such as joint hypermobility (29%), hirsutism (33%), and naevi (50%) were also reported" (PMID: 31643139).

Phenotype	Type	Frequency	Onset	Suggested HPO
Macrocephaly	physical	~all	postnatal/childhood	HP:0000256
Behavioral difficulties	behavioral	~100%	childhood	HP:0000708
Autism spectrum disorder	behavioral	~89%	childhood	HP:0000729
Intellectual disability	cognitive	~83%	childhood	HP:0001249
Aggressive outbursts	behavioral	~83%	childhood	HP:0000718
Tall/advanced stature	physical	~50%	postnatal	HP:0000098
Obesity	physical	~50%	childhood	HP:0001513
Naevi	physical sign	~50%	variable	HP:0001054
Hirsutism	physical sign	~33%	variable	HP:0001007
Joint hypermobility	physical	~29%	childhood	HP:0001382
Speech delay	developmental	common	early childhood	HP:0000750
Motor delay	developmental	common	early childhood	HP:0001270
Advanced carpal ossification	radiographic	common	childhood	HP:0011834
Chiari I malformation	structural	reported subset	congenital	HP:0002344
Seizures	neurological	reported subset	childhood	HP:0001250
Facial dysmorphism	physical	reported	congenital	HP:0001999
Recurrent otitis media	clinical	reported	childhood	HP:0000403
Bilateral condylar hyperplasia	physical (rare)	single report	adolescence	—

Severity/progression: Variable expressivity, ranging from a mild adult overgrowth presentation "without neurological symptoms" (PMID: 33248444) to classic ID/ASD/overgrowth. Core neurodevelopmental features are generally stable (non-progressive) but lifelong. A rare/unusual manifestation, bilateral condylar hyperplasia, has been reported as part of the expanding phenotype (PMID: 40892041).

Quality-of-life impact: Driven mainly by ID, ASD, and behavioral difficulties (impact on communication, education, independence, and family/caregiver burden). Formal QoL instrument data (EQ-5D/SF-36/PROMIS) are not published for LLS.

4. Genetic / Molecular Information

Causal gene: SETD2 (SET domain-containing 2), HGNC:18420, OMIM *612778, locus 3p21.31; encodes the sole somatic H3K36 trimethyltransferase.
Variant classification (ACMG/AMP): Pathogenic/likely-pathogenic LoF variants; the SETD2 episignature helps reclassify VUS (PMID: 40104911).
Variant types: Truncating (~69%: frameshift, nonsense, splice-site) and missense (~31%) (PMID: 31643139). Representative: c.2028delT (p.P677LfsX19) (PMID: 26084711).
Allele frequency: Pathogenic variants are private/de novo; absent from population databases (gnomAD) — consistent with strong SETD2 constraint against LoF.
Somatic vs germline: LLS variants are germline (constitutional), de novo. Somatic SETD2 LoF is a separate, well-established oncogenic event (renal cell carcinoma, leukemia, glioma).
Functional consequence: Loss of function / haploinsufficiency for LLS. By contrast, codon-1740 missense variants likely act through a non-LoF mechanism (PMID: 32710489).
Modifier genes: None established.
Epigenetic information: A distinctive DNA-methylation episignature characterizes LLS/SETD2-related disorders and is detectable by EpiSign (PMID: 40104911).
Chromosomal abnormalities: Interstitial 3p21.31 deletions encompassing SETD2 can produce overlapping features (developmental delay, ID, dysmorphism) (PMID: 27385966).

Genotype–phenotype dichotomy at codon 1740: Rabin (2020) identified 15 individuals with de novo codon-1740 variants — p.Arg1740Trp (n=12) → RAPAS (microcephaly, profound ID, multi-organ anomalies; MIM 620155) and p.Arg1740Gln (n=3) → MRD70 (moderate-severe ID). "The phenotype of Group 1 includes microcephaly, profound intellectual disability, congenital anomalies affecting several organ systems, and similar facial features," and "the clinical features seen in individuals with variants affecting codon 1740 are more severe suggesting an alternative mechanism, such as gain of function, effects on epigenetic regulation, or posttranslational" modification (PMID: 32710489).

5. Environmental Information

No environmental, lifestyle, or infectious factors are known to cause or trigger LLS. It is a monogenic de novo dominant disorder. Obesity, when present, is a phenotypic feature partly amenable to lifestyle/nutritional management rather than an etiologic exposure (PMID: 29681085). No infectious agents apply.

6. Mechanism / Pathophysiology

Central node — SETD2 dual enzymatic activity. SETD2 "is a dual-function methyltransferase for histones and microtubules and plays an important role for transcriptional regulation, genomic stability, and cytoskeletal functions" (PMID: 32710489); it has "chromatocytoskeletal activity, methylating both histones and microtubules" (PMID: 32620673).

Chromatin arm (H3K36me3). As the sole somatic H3K36me3 writer, SETD2 loss reduces transcriptional fidelity (allowing cryptic transcription), impairs co-transcriptional splicing, and compromises DNA repair and genomic stability. In the brain, the H2A.z–Setd2–H3K36me3 axis drives neurogenesis: "H2A.z regulates embryonic neurogenesis by targeting Nkx2-4 through interaction with Setd2, thereby promoting H3K36me3 modification to activate the transcription of Nkx2-4" (PMID: 29294103).

Cytoskeletal arm (α-TubK40me3). SETD2 methylates α-tubulin at Lys40; this mark is enriched in mouse cortex at E14–E16 and is required for neuronal migration: "Knockdown of α-tubulin methyltransferase SETD2 at E14 leads to the defects in neuronal migration, which could be restored by overexpressing either a cytoplasm-localized SETD2 truncation or α-TubK40me3-mimicking mutant" (PMID: 34226540). Loss also degrades spindle integrity: "SETD2 is a dual-function methyltransferase important for methylation of histone H3 at lysine 36 and α-tubulin in spindle microtubules" (PMID: 41827754), producing chromatin bridges, micronuclei, and aneuploidy. The α-TubK40me3 regulatory triad comprises writer SETD2, reader PBRM1, and eraser KDM4A (PMID: 41171906); a Drosophila Set2 E741Q model confirms spindle defects (PMID: 38290049).

Candidate overgrowth mechanism. In one LLS case, patient cells "showed enhanced tyrosine phosphorylation and transcriptional activity of signal transducer and activator of transcription 5b (STAT5b) and increased IGF-1 expression induced by GH" (PMID: 33248444), implicating a GH→STAT5b→IGF-1 axis in postnatal overgrowth (single case; not yet generalized).

Suggested ontology terms: - GO (BP): histone H3-K36 trimethylation (GO:0010452); DNA repair (GO:0006281); microtubule cytoskeleton organization (GO:0000226); mitotic spindle organization (GO:0007052); neuron migration (GO:0001764); regulation of transcription elongation. - GO (CC): nucleus (GO:0005634); chromatin (GO:0000785); microtubule (GO:0005874); mitotic spindle (GO:0072686). - CL: neuron (CL:0000540); cortical projection neuron; radial glial/neural progenitor cell (CL:0000047). - CHEBI: S-adenosyl-L-methionine (CHEBI:15414, methyl donor).

7. Anatomical Structures Affected

Organ/system level: Central nervous system (primary) — cerebral cortex; brain (UBERON:0000956, UBERON:0000955), reflected in ID, ASD, seizures, and posterior-fossa Chiari I malformation. Skeletal system — macrocephaly, tall stature, advanced carpal ossification, rare condylar hyperplasia. Integument — naevi, hirsutism. Endocrine/growth axis — candidate GH/IGF-1 involvement.
Tissue/cell level: Nervous tissue (cortical neurons, neural progenitors CL:0000047); connective tissue laxity (joint hypermobility).
Subcellular level: Nucleus/chromatin (H3K36me3) and microtubule/mitotic spindle (α-TubK40me3).
Localization/lateralization: Bilateral/systemic; no lateralization (condylar hyperplasia notably reported as bilateral, PMID: 40892041).

8. Temporal Development

Onset: Congenital-to-pediatric; overgrowth is characteristically postnatal (not prenatal). Developmental delay and behavioral features emerge in early childhood.
Progression: Chronic, lifelong; core neurodevelopmental features are generally stable/non-progressive. No relapsing-remitting course; not a repeat-expansion disorder (no genetic anticipation).
Critical periods: Embryonic cortical neurogenesis and neuronal migration (mouse E14–E16 equivalents) represent the mechanistic windows of vulnerability.

9. Inheritance and Population

Epidemiology: Ultra-rare — ~50 reported patients (PMID: 40104911); Orphanet prevalence <1/1,000,000 (ORPHA:457485). Precise incidence unknown.
Inheritance: Autosomal dominant; near-universally de novo. Chen (2021) "manually curate[d] 17 SETD2 de novo variants in 17 individuals from published literature" (PMID: 33766796).
Penetrance/expressivity: High penetrance with variable expressivity, from mild (no neurological symptoms, PMID: 33248444) to classic severe.
Recurrence risk: Low for parents of an affected child (de novo), with a residual caveat for gonadal mosaicism.
Founder effects / consanguinity / carrier frequency: None established; not a recessive/carrier disorder.
Demographics: No ethnic predilection, geographic clustering, or clear sex bias; both sexes affected.

10. Diagnostics

Recommended approach: Molecular confirmation of a heterozygous pathogenic/likely-pathogenic SETD2 variant.
Sequencing: Trio whole-exome (WES) or whole-genome (WGS) sequencing; overgrowth/intellectual-disability multigene panels (which include SETD2 alongside NSD1, EZH2, NFIX, DNMT3A, PTEN, etc.). Macrocephaly/ASD panels have detected pathogenic variants in such cohorts (PMID: 40282429).
Chromosomal microarray (CMA): Detects 3p21.31 deletions encompassing SETD2 (PMID: 27385966).
Epigenomic diagnostics: The SETD2 EpiSign DNA-methylation episignature supports diagnosis and VUS reclassification — "DNA methylation study by EpiSign assay confirmed the presence of an episignature profile compatible with SETD2-related disorders" (PMID: 40104911).
Supportive workup: Growth charts (macrocephaly/tall stature), skeletal survey (advanced bone age), brain MRI (Chiari I), EEG if seizures, developmental/ASD assessment.
Differential diagnosis: Other Sotos-like epigenetic overgrowth syndromes — Sotos (NSD1), Weaver (EZH2), Malan (NFIX), Tatton-Brown-Rahman (DNMT3A), Beckwith-Wiedemann (11p15 imprinting), and PTEN hamartoma tumor syndrome. LLS is explicitly placed here: "The SETD2 gene encoding a H3K36 trimethyltransferase is implicated in Sotos-like syndrome" (PMID: 31643139).
Screening: No newborn or carrier screening (de novo dominant); molecular testing is diagnostic, not screening.

11. Outcome / Prognosis

Survival/mortality: Life expectancy is not clearly reduced in classical LLS; no disease-specific mortality data published.
Morbidity/function: Driven by ID, ASD, and behavioral difficulties affecting communication, education, independence, and caregiver burden; obesity and Chiari I add complications.
Disease course: Chronic, lifelong, generally stable neurodevelopmental features.
Tumor risk (uncertain): SETD2 is a canonical tumor suppressor — "SETD2 is the only known enzyme that catalyzes H3K36me3 in somatic cells and is implicated in tumor suppression across multiple cancer types" (PMID: 40948406) — and a constitutional multi-tumor case exists, prompting discussion that "given the implication of somatic SETD2 variants in benign and malignant tumors, the implication of these SETD2 constitutional variants in tumorigenesis is discussed" (PMID: 40104911). However, classical LLS cohorts have not established elevated cancer risk, and surveillance is not standardized.
Prognostic factors: Variant type/position may influence severity (LoF → LLS overgrowth; codon-1740 → severe growth-restricted RAPAS/MRD70).

12. Treatment

There is no disease-specific or curative therapy; management is supportive and multidisciplinary.

Developmental/rehabilitative: Early intervention; speech, occupational, and physical therapy (NCIT rehabilitation-intervention terms).
Behavioral/ASD: Behavioral therapy; pharmacologic management of aggression when indicated.
Neurological: Anti-seizure medication for epilepsy; neurosurgical evaluation for symptomatic Chiari I malformation.
Metabolic: Obesity prevention/nutritional management — "prevention of obesity should be an important point of attention for patients diagnosed with a SETD2-related overgrowth syndrome" (PMID: 29681085).
Advanced/experimental therapeutics: No gene, RNA-based, cell, or targeted therapies are available or in clinical trials for LLS.
Pharmacogenomics: No LLS-specific pharmacogenomic guidance.

13. Prevention

Primary prevention: Not applicable for a de novo dominant disorder.
Genetic counseling: Convey typically low recurrence risk (with a caveat for possible parental gonadal mosaicism). Prenatal or preimplantation genetic testing is possible when a familial variant is known.
Secondary/tertiary prevention: Developmental surveillance, obesity prevention, and management of complications (seizures, Chiari I).
Screening: No population or newborn screening; cascade testing generally not applicable.

14. Other Species / Natural Disease

Orthologs: SETD2 is highly conserved — mouse Setd2, zebrafish setd2, Drosophila Set2, yeast Set2.
Natural disease: No well-characterized naturally occurring animal equivalent of LLS is documented (no established OMIA entry); disease relevance is through engineered models.
Comparative biology: The H3K36me3 methyltransferase function is deeply conserved: in zebrafish "Setd2 is the only enzyme that catalyzes histone H3 lysine 36 trimethylation (H3K36me3) on virtually all actively transcribed protein-coding genes" (PMID: 33088589); tumor-suppressor and spindle functions are conserved from Drosophila (PMID: 38290049) to mammals.
Zoonotic/transmission: Not applicable (genetic disorder).

15. Model Organisms

Model	System	Key finding	Relevance to LLS	PMID
Mouse constitutive KO	Mammalian	Embryonic lethal (vascular/mesodermal defects)	Confirms essentiality; requires conditional/het models	(established)
Mouse H2A.z brain-specific deletion	Mammalian	H2A.z–Setd2–H3K36me3 → Nkx2-4 drives neurogenesis; deletion → cortical neurogenesis defects, abnormal dendrites, learning/memory deficits	Models neurodevelopmental arm	29294103
Mouse in-utero SETD2 knockdown (E14)	Mammalian	Neuronal migration defects; rescued by cytoplasmic SETD2 / α-TubK40me3 mimic / Taxol	Models cytoskeletal (migration) arm	34226540
Zebrafish setd2	Vertebrate	Sole H3K36me3 writer on transcribed genes; essential in development	Validates enzyme uniqueness	33088589
Drosophila Set2 E741Q	Invertebrate	↓ H3K36me3 + mitotic-spindle defects	Models spindle/genomic-stability arm	38290049

Model characteristics / limitations: Constitutive knockouts are embryonic lethal and cannot model the heterozygous adult phenotype; most models isolate one mechanistic arm (chromatin or cytoskeleton); behavioral and overgrowth features are not yet co-recapitulated in a single dose-accurate mammalian model. Resources: MGI (Setd2), ZFIN (setd2), FlyBase (Set2).

Mechanistic Model / Interpretation

Heterozygous de novo SETD2 loss-of-function variant
 (truncating ~69% / missense ~31%)
              |
     ~50% reduction in SETD2 dosage
              |
┌─────────────────────┴──────────────────────┐
│                                             │
   NUCLEAR / CHROMATIN ARM                    CYTOSKELETAL ARM
   ↓ H3K36me3                                 ↓ α-tubulin K40me3
   • transcription fidelity ↓                 • neuronal polarization ↓
   • cryptic transcription ↑                  • neuronal MIGRATION ↓
   • splicing dysregulation                   • mitotic spindle integrity ↓
   • DNA repair / genomic stability ↓         • aneuploidy / micronuclei ↑
│                                             │
│  H2A.z–Setd2–H3K36me3 → Nkx2-4              │  (writer SETD2 /
│  → cortical neurogenesis                    │   reader PBRM1 /
│                                             │   eraser KDM4A)
└─────────────────────┬──────────────────────┘
              |
   Impaired cortical neurodevelopment + dysregulated growth signaling
(candidate GH → STAT5b → IGF-1 axis in some patients)
              |
   ┌──────────────────────────┴───────────────────────────┐
   │ NEURODEVELOPMENTAL: ID (~83%), ASD (~89%),            │
   │   behavior (~100%), speech/motor delay, seizures      │
   │ OVERGROWTH: macrocephaly (~all), tall stature/         │
   │   obesity (~50%), advanced carpal ossification        │
   └───────────────────────────────────────────────────────┘

Upstream → downstream logic: The SETD2 LoF variant is the single upstream trigger. Its two enzymatic outputs (H3K36me3 and α-TubK40me3) act as parallel intermediate nodes. The chromatin arm predominantly explains transcriptional/growth dysregulation and neurogenesis defects; the cytoskeletal arm explains neuronal migration and mitotic phenotypes. Both converge on the developing cerebral cortex, yielding the combined overgrowth-plus-neurodevelopmental picture. The codon-1740 growth-restricted disorders (RAPAS/MRD70) at the same locus arise via a distinct (non-LoF) mechanism, showing that dosage and mechanism dictate divergent outcomes.

Evidence Base

PMID	Title (abbrev.)	Evidence type	Supports section(s)
26084711	SETD2 mutation in a child with autism, ID, epilepsy (Lumish 2015)	Human clinical (first case)	1, 2, 4
31643139	SETD2-related overgrowth: four new patients + review (Marzin 2019)	Human clinical (cohort n=13)	1–4, 10
32710489	Genotype-phenotype at codon 1740 of SETD2 (Rabin 2020)	Human clinical + mechanism	4, 6
40104911	Abnormal DNA methylation → syndromic multiple-tumor phenotype	Human clinical + epigenetics	1, 4, 9, 10, 11
33248444	LLS case: enhanced GH signaling	Human clinical + in vitro	3, 6, 9
37372360	Clinical heterogeneity / three distinct entities	Human clinical	1, 4
33766796	Mutation pattern & genotype-phenotype of SETD2 (Chen 2021)	Human clinical (curation)	9
29681085	Two novel cases expanding the phenotype	Human clinical	12
27385966	3p21.31 interstitial deletion	Human clinical (CNV)	4, 10
40282429	Macrocephaly/ASD gene-panel cohort	Human clinical	10
40892041	Bilateral condylar hyperplasia in LLS	Human clinical (case)	3
29294103	H2A.z deletion → cortical neurogenesis defects	Model organism (mouse)	6, 15
33088589	Setd2 sole H3K36me3 writer (zebrafish)	Model organism	6, 14, 15
34226540	α-TubK40me3 required for neuronal migration	Model organism (mouse)	6, 15
32620673	Chromatocytoskeletal co-regulation by methylation	Review/mechanism	6
41827754	SETD2 inhibition → genomic instability	In vitro/mechanism	6
41171906	KDM4A is the α-tubulin demethylase	In vitro/mechanism	6
38290049	Drosophila Set2 E741Q → spindle defects	Model organism	6, 14, 15
40948406	SETD2 tumor suppression (KRAS model)	Model organism/mechanism	11
40755378	Setd2 + Kras → JMML, MEK-inhibitor sensitivity	Model organism	11
41654133	SETD2 L1609P (leukemia) disrupts activity	In vitro/structural	11
37921122	Cellular/molecular functions of SETD2 in CNS	Review	6

Limitations and Knowledge Gaps

Small sample size. All clinical conclusions rest on ~50 reported patients (largest single cohort n=13); frequency estimates carry wide confidence intervals and possible ascertainment bias toward severe cases.
No natural-history or registry data. Adult trajectories, life expectancy, and validated quality-of-life metrics are undocumented.
Tumor risk unresolved. SETD2 is a tumor suppressor and a constitutional multi-tumor case exists, but LLS-cohort cancer risk and the value of surveillance are unknown.
Mechanistic attribution. The relative contribution of the chromatin (H3K36me3) versus cytoskeletal (α-TubK40me3) arm to specific human phenotypes has not been dissected in patients.
Intra-LLS genotype–phenotype. Beyond the codon-1740 dichotomy, predictors of severity within LLS (truncation position, residual protein) are unestablished.
No dose-accurate mammalian LLS model. Constitutive KO is lethal; a heterozygous/knock-in model co-recapitulating overgrowth and behavior is lacking.
Overgrowth driver. The GH/STAT5b/IGF-1 finding is from a single case and not generalized.

Proposed Follow-up Experiments / Actions

Establish an international LLS registry to aggregate genotype, phenotype frequencies, growth trajectories, tumor events, and QoL — powering robust penetrance/expressivity and prognosis estimates.
Generate a dose-accurate mouse model (Setd2 heterozygous LoF or patient-specific knock-in) and phenotype for macrocephaly, cortical lamination, dendritic morphology, and behavior.
Refine and standardize the SETD2 EpiSign episignature for VUS reclassification and test whether episignature features distinguish LLS from RAPAS/MRD70 or correlate with severity.
Prospective tumor-surveillance pilot in constitutional SETD2-variant carriers to quantify malignancy risk and evaluate whether imaging/biochemical screening is justified.
Dissect the two mechanistic arms using separation-of-function alleles in patient iPSC-derived cortical organoids/neurons to map which clinical features track with each activity.
Interrogate the GH/STAT5b/IGF-1 axis across multiple patients (serum IGF-1; GH-stimulated STAT5b phosphorylation) to test generalizability and druggability of the overgrowth driver.
Systematic genotype–phenotype meta-analysis of all published SETD2 variants (LLS vs. MRD70 vs. RAPAS) to build a mechanism-aware variant-interpretation framework.

Consensus Answer

Luscan-Lumish syndrome (MONDO:0014916; OMIM #616831) is an ultra-rare, autosomal-dominant, near-universally de novo overgrowth and neurodevelopmental disorder caused by heterozygous loss-of-function variants in SETD2, the sole somatic H3K36 trimethyltransferase. SETD2 haploinsufficiency reduces two methyl marks — histone H3K36me3 (transcriptional fidelity, splicing, DNA repair) and α-tubulin K40me3 (neuronal migration and mitotic-spindle integrity) — producing postnatal overgrowth, macrocephaly, obesity, intellectual disability (~83%), autism (~89%), and behavioral difficulties (~100%). Diagnosis is molecular (trio WES/WGS or overgrowth-ID panels plus a SETD2 DNA-methylation episignature), and management is entirely supportive and multidisciplinary because no disease-specific or curative therapy exists.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	22
Resolved	22
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	17
Quoted claims found in source	17
Quoted claims not found in source	0
References weighed for topical relevance	22
On topic	11
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Differential Diagnoses

Source YAML

References & Deep Research

References

Deep Research

Luscan-Lumish Syndrome: Comprehensive Disease Characteristics Report

Summary

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

Evidence Base

Limitations and Knowledge Gaps

Proposed Follow-up Experiments / Actions

Consensus Answer

Artifacts

Reference Validation